http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-812830-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
filingDate 1955-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1959-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-812830-A
titleOfInvention Aminoisoxazolidone compounds
abstract The invention comprises compounds of the formula <FORM:0812830/IV (b)/1> in which X, Y and Z are H or alkyl, aralkyl or aryl of 1-8 carbon atoms, and R and R2 are H or alkyl or aralkyl of 1-8 carbon atoms. These are made by treating with a base compounds of the formula R-NH-O-CXY-CZ (NHR2)-COOR4 or acid addition salts thereof, where R4 is C1-C8 alkyl. The base used for cyclisation is preferably an aqueous alkali metal hydroxide in amount and concentration such that the pH after the reaction is 10-11. The mixture is preferably left to stand for 10-30 minutes and then acidified with an acid (e.g. hydrochloric or acetic), if desired after addition of an ethanol-isopropanol mixture and removal of inorganic salts. The product then crystallizes or is adsorbed on an anion-exchange resin and thence removed with water in the presence of carbon dioxide. Examples show the preparation of 4-amino-3-isoxazolidone and its 5-methyl derivative, the former being resolved with tartaric acid. Starting materials are mentioned in which R and R2 are also methyl, propyl and benzyl, X and Y are methyl, ethyl or phenyl and Z is methyl or benzyl. The products are anti-bacterial agents for animals and plants. The starting materials are prepared as follows: a 4-carbalkoxy-oxazoline of the formula <FORM:0812830/IV (b)/2> where R3 is C1-C8 alkyl, aryl or aralkyl and R5 is C1-C8 alkyl, is treated with an hydroxylamine R-NHOH in the presence of a base under anhydrous conditions to give an hydroxylamide <FORM:0812830/IV (b)/3> and the latter reacted with R2Q in an inert solvent to form <FORM:0812830/IV (b)/4> where Q is chlorine, bromine or iodine. Alkaline cyclisation in a water-miscible solvent produces a 4-acylamino-isoxazolidone, <FORM:0812830/IV (b)/5> which when treated with R4OH under acidic conditions forms the required compound R-NH -O-CXY-CZ(NHR2)-COOR4. Typical compounds and reagents are specified for each step. Examples are given of the preparation of 2 - phenyl - 4 - carbohydroxamido - 2 - oxazoline, 2 - phenyl - 4 - carbohydroxamide - 5-methyl - 2 - oxazoline, a - benzamido - b - chloropropionyl - hydroxylamine, a - benzamido - b -chloro - butyryl - hydroxylamine, 4 - benzamido - 3 - isoxazolidone, 4 - benzamido - 5-methyl - 3 - isoxazolidone, and methyl a -amino - b - aminoxy - propionate and butyrate as dihydrochlorides. 2 - Phenyl - 4 - carbohydroxamido - 2 - oxazoline is made by esterifying serine with ethanol in the presence of dry hydrogen chloride and reacting the resulting ester hydrochloride with benzimido ethyl ether (from benzonitrile, ethanol and dry hydrogen chloride).
priorityDate 1954-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556587
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24408
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526605
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID280
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559213
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426261351
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID807
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7505
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410440819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21225539
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447315
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24972933
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449831254
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22179027
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID787
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490743
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431919258
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18763383
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154089463
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457698762
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71077
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408497309
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104775
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419578945
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID160955
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457192620
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447561645
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554831
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393346
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483812

Total number of triples: 55.